FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2115822788> ?p ?o ?g. }

• W2115822788 endingPage "837" @default.
• W2115822788 startingPage "827" @default.
• W2115822788 abstract "Background Several targeted drugs are approved for treatment of patients with metastatic renal-cell cancer, but no validated biomarkers are available for prediction of clinical outcome. We aimed to assess the prognostic and predictive associations of pretreatment plasma concentrations of cytokine and angiogenic factors (CAFs) with data from a phase 2 and a phase 3 trial of pazopanib treatment. Methods We used a three-step approach for screening, confirmation, and validation of prospective CAF biomarkers. We screened 17 CAFs in 129 patients who had the greatest or least tumour shrinkage in a phase 2 trial of 215 patients treated with pazopanib. We confirmed associations of candidate CAFs (those identified in the screening and from previous studies) with tumour response and progression-free survival (PFS) in 215 patients from this phase 2 trial with an independent analytical platform. We validated confirmed markers in 344 patients from a randomised, placebo-controlled, phase 3 clinical study of pazopanib. Findings Five candidate markers emerged from initial screening—interleukin 6, interleukin 8, hepatocyte growth factor (HGF), tissue inhibitor of metalloproteinases (TIMP)-1, and E-selectin. Confirmatory analyses identified associations of interleukin 6, interleukin 8, VEGF, osteopontin, E-selectin, and HGF with continuous tumour shrinkage or PFS in patients treated with pazopanib. In the validation set of samples from the phase 3 trial, patients treated with pazopanib who had high concentrations (relative to median) of interleukin 8 (p=0·006), osteopontin (p=0·0004), HGF (p=0·010), and TIMP-1 (p=0·006) had shorter PFS than did those with low concentrations. In the placebo group, high concentrations of interleukin 6 (p<0·0001), interleukin 8 (p=0·002), and osteopontin (p<0·0001) were all prognostically associated with shorter PFS. These factors were stronger prognostic markers than were standard clinical classifications (Eastern Cooperative Oncology Group, Memorial Sloan-Kettering Cancer Center, and Heng criteria). High concentrations of interleukin 6 were predictive of improved relative PFS benefit from pazopanib compared with placebo (pinteraction=0·009); standard clinical classifications were not predictive of PFS benefit. Interpretation CAF profiles could provide prognostic information beyond that of standard clinical classification and identify markers predictive of pazopanib benefit in patients with metastatic renal-cell carcinoma. Further studies of the predictive effects of these markers in different populations and with different drugs (eg, mTOR inhibitors) are warranted. Funding GlaxoSmithKline. Several targeted drugs are approved for treatment of patients with metastatic renal-cell cancer, but no validated biomarkers are available for prediction of clinical outcome. We aimed to assess the prognostic and predictive associations of pretreatment plasma concentrations of cytokine and angiogenic factors (CAFs) with data from a phase 2 and a phase 3 trial of pazopanib treatment. We used a three-step approach for screening, confirmation, and validation of prospective CAF biomarkers. We screened 17 CAFs in 129 patients who had the greatest or least tumour shrinkage in a phase 2 trial of 215 patients treated with pazopanib. We confirmed associations of candidate CAFs (those identified in the screening and from previous studies) with tumour response and progression-free survival (PFS) in 215 patients from this phase 2 trial with an independent analytical platform. We validated confirmed markers in 344 patients from a randomised, placebo-controlled, phase 3 clinical study of pazopanib. Five candidate markers emerged from initial screening—interleukin 6, interleukin 8, hepatocyte growth factor (HGF), tissue inhibitor of metalloproteinases (TIMP)-1, and E-selectin. Confirmatory analyses identified associations of interleukin 6, interleukin 8, VEGF, osteopontin, E-selectin, and HGF with continuous tumour shrinkage or PFS in patients treated with pazopanib. In the validation set of samples from the phase 3 trial, patients treated with pazopanib who had high concentrations (relative to median) of interleukin 8 (p=0·006), osteopontin (p=0·0004), HGF (p=0·010), and TIMP-1 (p=0·006) had shorter PFS than did those with low concentrations. In the placebo group, high concentrations of interleukin 6 (p<0·0001), interleukin 8 (p=0·002), and osteopontin (p<0·0001) were all prognostically associated with shorter PFS. These factors were stronger prognostic markers than were standard clinical classifications (Eastern Cooperative Oncology Group, Memorial Sloan-Kettering Cancer Center, and Heng criteria). High concentrations of interleukin 6 were predictive of improved relative PFS benefit from pazopanib compared with placebo (pinteraction=0·009); standard clinical classifications were not predictive of PFS benefit. CAF profiles could provide prognostic information beyond that of standard clinical classification and identify markers predictive of pazopanib benefit in patients with metastatic renal-cell carcinoma. Further studies of the predictive effects of these markers in different populations and with different drugs (eg, mTOR inhibitors) are warranted." @default.
• W2115822788 created "2016-06-24" @default.
• W2115822788 creator A5004985848 @default.
• W2115822788 creator A5011794417 @default.
• W2115822788 creator A5017047559 @default.
• W2115822788 creator A5035163601 @default.
• W2115822788 creator A5046214153 @default.
• W2115822788 creator A5048380048 @default.
• W2115822788 creator A5050649350 @default.
• W2115822788 creator A5052414597 @default.
• W2115822788 creator A5056267838 @default.
• W2115822788 creator A5059272502 @default.
• W2115822788 creator A5064792807 @default.
• W2115822788 creator A5072800302 @default.
• W2115822788 date "2012-08-01" @default.
• W2115822788 modified "2023-10-18" @default.
• W2115822788 title "Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials" @default.
• W2115822788 cites W1979571949 @default.
• W2115822788 cites W1982476665 @default.
• W2115822788 cites W1999966467 @default.
• W2115822788 cites W2001783033 @default.
• W2115822788 cites W2010160635 @default.
• W2115822788 cites W2011810742 @default.
• W2115822788 cites W2029126579 @default.
• W2115822788 cites W2029169364 @default.
• W2115822788 cites W2039035303 @default.
• W2115822788 cites W2068521555 @default.
• W2115822788 cites W2087186976 @default.
• W2115822788 cites W2099752220 @default.
• W2115822788 cites W2100669312 @default.
• W2115822788 cites W2101019048 @default.
• W2115822788 cites W2103305666 @default.
• W2115822788 cites W2115201803 @default.
• W2115822788 cites W2117454747 @default.
• W2115822788 cites W2118325137 @default.
• W2115822788 cites W2122730895 @default.
• W2115822788 cites W2123830992 @default.
• W2115822788 cites W2125651014 @default.
• W2115822788 cites W2135400147 @default.
• W2115822788 cites W2141236760 @default.
• W2115822788 cites W2143782771 @default.
• W2115822788 cites W2146853858 @default.
• W2115822788 cites W2149456801 @default.
• W2115822788 cites W2151229627 @default.
• W2115822788 cites W2153826097 @default.
• W2115822788 cites W2157262448 @default.
• W2115822788 cites W2160888189 @default.
• W2115822788 cites W2162424705 @default.
• W2115822788 doi "https://doi.org/10.1016/s1470-2045(12)70241-3" @default.
• W2115822788 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22759480" @default.
• W2115822788 hasPublicationYear "2012" @default.
• W2115822788 type Work @default.
• W2115822788 sameAs 2115822788 @default.
• W2115822788 citedByCount "234" @default.
• W2115822788 countsByYear W21158227882012 @default.
• W2115822788 countsByYear W21158227882013 @default.
• W2115822788 countsByYear W21158227882014 @default.
• W2115822788 countsByYear W21158227882015 @default.
• W2115822788 countsByYear W21158227882016 @default.
• W2115822788 countsByYear W21158227882017 @default.
• W2115822788 countsByYear W21158227882018 @default.
• W2115822788 countsByYear W21158227882019 @default.
• W2115822788 countsByYear W21158227882020 @default.
• W2115822788 countsByYear W21158227882021 @default.
• W2115822788 countsByYear W21158227882022 @default.
• W2115822788 countsByYear W21158227882023 @default.
• W2115822788 crossrefType "journal-article" @default.
• W2115822788 hasAuthorship W2115822788A5004985848 @default.
• W2115822788 hasAuthorship W2115822788A5011794417 @default.
• W2115822788 hasAuthorship W2115822788A5017047559 @default.
• W2115822788 hasAuthorship W2115822788A5035163601 @default.
• W2115822788 hasAuthorship W2115822788A5046214153 @default.
• W2115822788 hasAuthorship W2115822788A5048380048 @default.
• W2115822788 hasAuthorship W2115822788A5050649350 @default.
• W2115822788 hasAuthorship W2115822788A5052414597 @default.
• W2115822788 hasAuthorship W2115822788A5056267838 @default.
• W2115822788 hasAuthorship W2115822788A5059272502 @default.
• W2115822788 hasAuthorship W2115822788A5064792807 @default.
• W2115822788 hasAuthorship W2115822788A5072800302 @default.
• W2115822788 hasConcept C121608353 @default.
• W2115822788 hasConcept C126322002 @default.
• W2115822788 hasConcept C143998085 @default.
• W2115822788 hasConcept C2778439243 @default.
• W2115822788 hasConcept C2779490328 @default.
• W2115822788 hasConcept C2780804394 @default.
• W2115822788 hasConcept C31760486 @default.
• W2115822788 hasConcept C535046627 @default.
• W2115822788 hasConcept C71924100 @default.
• W2115822788 hasConceptScore W2115822788C121608353 @default.
• W2115822788 hasConceptScore W2115822788C126322002 @default.
• W2115822788 hasConceptScore W2115822788C143998085 @default.
• W2115822788 hasConceptScore W2115822788C2778439243 @default.
• W2115822788 hasConceptScore W2115822788C2779490328 @default.
• W2115822788 hasConceptScore W2115822788C2780804394 @default.
• W2115822788 hasConceptScore W2115822788C31760486 @default.
• W2115822788 hasConceptScore W2115822788C535046627 @default.
• W2115822788 hasConceptScore W2115822788C71924100 @default.
• W2115822788 hasIssue "8" @default.

• next